Hematopoietic allogeneic stem cell transplantation (SCT) is an established method for the treatment of hematologic malignancies and increasingly used also for older patients as well as other neoplasias. Owing to transplantation across major or, more importantly, minor histocompatibility barriers, severe inflammatory reactions, such as acute and chronic graft-versus-host disease (GvHD), veno-occlusive disease (VOD), endothelial leakage syndrome (ELS), thrombotic thrombocytopenic purpura (TTP) and microangiopathic hemolytic anemia (microangiopathy), can occur. 1 Previous work from our group and other investigators strongly argues that almost all of these complications are associated with endothelial damage, which is the primary event of organ dysfunction following SCT, [2] [3] [4] and is initiated even prior to transplant. However, progress in the diagnosis, prediction of and prophylaxis against endothelial cell damage is limited so far. Studies on the presence of serum plasminogen activator inhibitor 1 as being indicative of VOD 5 as the major hepatic complication prompted us to examine whether in the course of SCT there are also apoptotic factors present.
We previously established an indicator cell system for the detection of apoptotic factors in SCT patients' serum. 6 Briefly, serum samples from 30 patients were collected at various time points pre and post SCT and used for the treatment of a microvascular endothelial cell line (CDC/ EU.-HMEC-1, further referred to as HMEC) as indicator cells. Endothelial damage was assessed by apoptosis assays using computer-guided microscopic analysis of DNA dye (DAPI, 4,6-diamidino-2-phenylindole, Sigma, Deisenhofen, Germany) stained HMEC after 48 h of treatment with 30% serum. Nuclear condensation as revealed by DAPI staining, in the absence of trypan blue uptake, is considered characteristic of apoptosis as opposed to necrosis. 7 Results are given as % apoptotic HMEC7s.d. out of n ¼ 4 microscopic fields. Spontaneous apoptosis in untreated (medium) HMEC was below 10% in all cases. The relevant results have been confirmed by an alternative apoptosis assay using flow cytometric detection of apoptosis-specific granularity (data not shown). Percent apoptotic HMEC was normalized to untreated control cells (apoptotic index, AI). The AI was set to a cutoff of 1.7 representing the mean AI of serum collected prior to any therapeutic intervention plus one s.d. For Tables 1 and 2 , the AI was taken from the maximum of HMEC apoptosis in the first 100 days post SCT. As a further control, the apoptosis-inducing capacity of serum from healthy control individuals was assessed and never reached patient levels (n ¼ 11, ranging from 10.571.6 to 13.473.9% apoptotic HMEC). Statistical analysis of these assays was done by the w 2 test. First, each patient was analyzed separately for the presence of apoptosis-inducing activity in the serum, which was then correlated with clinical outcome during the course of SCT. Figure 1 illustrates a typical example of a patient who developed GvHD. It is worthy to note that the first increase in the apoptotic activity of the serum can be observed at the time of engraftment (take), that is at the time when the number of nucleated cells exceeds 500/ml. This could reflect the toxic activity of donor monocytes that are known to release as yet unidentified endothelial toxic factors upon inflammatory activation. 8 Furthermore, the presence of HMEC apoptosis-inducing serum preceded episodes of acute as well as of chronic GvHD in this patient (indicated by arrows). This observation suggested the cumulative analysis of all 30 patients with regard to the development of GvHD and endothelial complications, such as microangiopathy. Therefore, the maximal normalized HMEC apoptosis in the first 100 days post SCT was defined as the AI, and patients were grouped by experimental distribution with a cutoff value of 1.7. This index was then compared to clinical outcome as no or mild GvHD (GvHD 0-I) vs severe and therapy-dependent GvHD (GvHD II-IV). Table 1 clearly demonstrates that an AI above 1.7 significantly (P ¼ 0.03) correlated with GvHD II-IV. Even more pronounced was the correlation of indicator cell apoptosis with episodes of microangiopathy in these patients (P ¼ 0.01).
Due to limited patient numbers, associations with further complications such as VOD were not evaluable. Preliminary analyses with sera of two patients that had received defibrotide for VOD therapy suggest that a decline in HMEC damage reflects the efficacy of defibrotide intervention (data not shown).
We also applied enzyme-linked immunosorbent assays (ELISA) for the serum levels of vascular cell adhesion molecule 1 (VCAM-1), which had been identified as an indicator of endothelial activation in addition to damage. 9 In line with the cited report, we found that maximal VCAM-1 release into patients' serum in the first 100 days post SCT correlated with GvHD (P ¼ 0.03; data not shown), suggesting that, indeed, serum analyses not only reflect damage but also allow activation of endothelial cells.
Taken together, these data suggest that the presence of EC damaging factors mirrors the course of transplantrelated complications, such as GvHD and microangiopathy, and may allow the monitoring of endothelium-protective therapies. Further analysis with higher patient numbers is warranted in order to predict endothelial complications and to develop risk-adapted prophylaxis. In these studies, analysis of endothelial apoptosis-inducing factors should be compared with more classical parameters of endothelial activation such as thrombomodulin or FVIII-related antigen as well as markers of activation of coagulation.
Furthermore, our indicator cell system could be combined with an individualized in vitro monitoring of the apoptotic susceptibility of patient-specific endothelial cells, isolated from the circulation, which should allow us to answer the question of whether endothelial damage is the result of nonspecific damage by conditioning, LPS and cytokines or the consequence of specific alloreaction of donor cells against host epithelia. Finally, the identification and characterization of the relevant toxic factors in the SCT patients' serum will also help to further modulate protective strategies. This is subject to ongoing studies in our laboratory. Preliminary analyses suggest that activated monocytes release this activity, which is also present in the supernatant of LPS-treated monocytes. AI ¼ apoptosis index ¼ maximal HMEC apoptosis in the first 100 days post SCT after treatment with 30% patients' serum for 48 h, normalized to untreated control HMEC. GvHD 0-I ¼ no or mild acute GvHD; GvHD II-IV ¼ severe and therapy-dependent acute GvHD; P ¼ 0.03.
Table 2
Endothelial cell apoptosis-inducing capacity in patients' serum correlates with severe microangiopathy
No microangiopathy
Severe microangiopathy AIo1.7 9 3 AI41. 7 5 13 AI ¼ apoptosis index ¼ maximal HMEC apoptosis in the first 100 days post SCT after treatment with 30% patients' serum for 48 h, normalized to untreated control HMEC. P ¼ 0.01.
